GABRIELLA PASZTOR: Open Payments
NPI 1659575231 · SUGAR LAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,352 in 108 payments from 10 companies in 2025. Trend: 2023 $2,357 · 2024 $1,727 · 2025 $2,352
Food & beverage: $2,240Education: $111
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 30 | $754 |
| Teva Pharmaceuticals USA, Inc. | 23 | $499 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $391 |
| E.R. Squibb & Sons, L.L.C. | 14 | $293 |
| Luye Pharma (USA) Ltd. | 13 | $165 |
| Alkermes, Inc. | 5 | $124 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Janssen Pharmaceuticals, Inc | 2 | $30 |
| Noven Therapeutics, LLC | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
Products named: INGREZZA, CAPLYTA, COBENFY, AUSTEDO XR, ERZOFRI EXTENDED-RELEASE, UZEDY, ARISTADA, LYBALVI.
Industry payments across TX — which companies pay providers there.
